(CercleFinance.com) – AstraZeneca announces that the results of a phase III trial carried out in Japan of acoramide in adults with transthyretin cardiac amyloidosis (ATTR-CM) are consistent with those of the global study phase III previously conducted by BridgeBio Pharma.
As a reminder, ATTR-CM is a rare, progressive and fatal disease, which leads to heart failure and high mortality rates within four years of diagnosis.
‘These results are further evidence that stabilizing transthyretins via acoramides can improve survival and reduce disease severity in patients by preventing further degradation of these proteins,’ commented Yukio Ando, professor in the Department of research on amyloidosis at Nagasaki International University (Japan).
“These positive results support our ambition to bring acoramides to people suffering from ATTR-CM in Japan as soon as possible,” added Marc Dunoyer, CEO of Alexion, the AstraZeneca subsidiary specializing in rare diseases.
The data will be presented at an upcoming medical meeting before being submitted to the Japanese health authority for regulatory review.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
